An Exploratory, Multi-Centre, Interventional, Prospective, Randomised, Double-Blind, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of AON-D21 in Patients with Severe Community-Acquired Pneumonia.
Latest Information Update: 06 Feb 2025
At a glance
- Drugs AON-D21 (Primary)
- Indications Community-acquired pneumonia
- Focus Adverse reactions
- Sponsors Aptarion Biotech
Most Recent Events
- 04 Feb 2025 Planned number of patients changed from 100 to 150.
- 04 Feb 2025 Planned End Date changed from 30 Jun 2025 to 30 Jun 2026.
- 04 Feb 2025 Planned primary completion date changed from 30 May 2025 to 30 May 2026.